Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
© Kim et al; licensee BioMed Central Ltd. 2012
Received: 22 December 2011
Accepted: 4 April 2012
Published: 4 April 2012
The phosphatidylinositol-3-kinase (PI3K-PKB), mitogen activated protein kinase (MEK-ERK) and the mammalian target of rapamycin (mTOR- p70S6K), are thought to regulate many aspects of tumour cell proliferation and survival. We have examined the utilisation of these three signalling pathways in a number of cell lines derived from patients with metastatic malignant melanoma of known PIK3CA, PTEN, NRAS and BRAF mutational status.
Western blotting was used to compare the phosphorylation status of components of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways, as indices of pathway utilisation.
Normal melanocytes could not be distinguished from melanoma cells on the basis of pathway utilisation when grown in the presence of serum, but could be distinguished upon serum starvation, where signalling protein phosphorylation was generally abrogated. Surprisingly, the differential utilisation of individual pathways was not consistently associated with the presence of an oncogenic or tumour suppressor mutation of genes in these pathways.
Utilisation of the PI3K-PKB, MEK-ERK and mTOR-p70S6K signalling pathways in melanoma, as determined by phosphorylation of signalling components, varies widely across a series of cell lines, and does not directly reflect mutation of genes coding these components. The main difference between cultured normal melanocytes and melanoma cells is not the pathway utilisation itself, but rather in the serum dependence of pathway utilisation.
KeywordsPhosphatidylinositol-3-kinase ERK mTOR Phosphorylation Melanoma and Melanocyte
Melanocytes are specialised cells found predominantly in the dermis, hair follicles and eyes, where they have a number of functions including the production of melanin  and of other factors including cytokines that act on peripheral cells . Melanomas are thought to arise from excessive proliferation of melanocyte precursors. Melanoma is the most aggressive form of skin cancer that is largely refractory to radiotherapy and cytotoxic drugs and the rapidity of appearance of metastatic lesions also compromises the efficacy of surgery .
Growth factor signalling pathways play a key role in relaying extracellular signals from growth factor binding to receptor tyrosine kinases on the plasma membrane to the nucleus via a cascade of phosphorylation events to regulate diverse processes such as proliferation, differentiation, survival and migration in normal melanocytes . The mitogen activated protein kinase (MAPK) signalling cascade is comprised of three-tier kinases that are activated when phosphorylated. The extracellular signal regulated kinase (ERK) pathway is the most studied of the mammalian MAPK pathways and is frequently deregulated in many cancers. ERK1 and ERK2 are activated upon phosphorylation by MEK, which is itself activated when phosphorylated by Raf . The phosphatidylinositol 3-kinase (PI3K) pathway is a second important intracellular signalling pathway and generates phosphatidylinositol-3,4,5-triphosphate (PIP3), a second messenger which induces downstream phosphorylation and activation of protein kinase B (PKB also known as Akt). The generation of the second messenger PIP3 is antagonised by the tumour suppressor phosphatase and tensin homologue (PTEN) . The mammalian target of rapamycin (mTOR) is a multidomain protein that is related to the PI3K enzymes and mediates signalling to regulate cellular growth and size . Both PI3K and MAPK pathways crosstalk extensively with the mTOR pathway to mediate different cellular functions through two different proteins, ribosomal protein S6 kinase (S6K) and 4E-binding protein (4EBP) .
A large fraction of melanomas harbour activating oncogenic or inactivating tumour suppressor gene mutations in the growth factor signalling pathways. Mutations in BRAF occur in 40%-60% of melanomas [9, 10] and 15%-30% of melanomas harbour activating NRAS mutations [10, 11]. It is notable that a large percentage of BRAF mutant melanomas also contain deletions or mutations in the PTEN gene . Although activating mutations of the p110 alpha isoform of PI3K (PIK3CA) also contribute to tumourigenesis in many types of cancer , they are found only at a low frequency in melanoma [13, 14]. However, the activation of the PI3K pathway is more commonly associated with melanoma. In BRAF mutant cells, loss of PTEN function plays an important role in the development of melanoma in mouse models, as BRAF mutations alone do not induce melanoma but melanoma develops when PTEN is deleted in melanocytes which harbour the BRAF mutation [15–17]. Current evidence indicates that the PI3K pathway play an important role in melanomas as inhibitors of the PI3K pathway synergise with inhibitors of the MAPK pathway in inhibiting the proliferation of many melanomas [18–20].
The discovery that most human melanomas harbour mutations in either BRAF or NRAS has led to the development of targeted therapies, such as inhibitors of MEK or BRAF . BRAF inhibitors have been developed that have quite dramatic effects on patients with mutant BRAF tumours [22, 23]. However responses are followed by the development of resistance [23, 24]. Recent studies have outlined the mechanisms whereby melanoma cells acquire resistance by bypassing the signalling pathway that is targeted by the drug. Thus there is a need to understand which signalling pathways are activated in melanoma and how these differ from those used by normal, benign melanocytes.
In an effort to provide a better understanding of the signalling pathways of normal and malignant melanocytes cells, we have cultured samples of surgically resected metastatic melanomas  and established over one hundred early passage melanoma cell lines [26–28]. We have analysed these cell lines at early passage for loss of PTEN and for mutations in BRAF, NRAS and PIK3CA and have chosen a subset that is representative of the main patterns of mutation. We have analysed the main signalling pathways of these cell lines and compared them to those of a cell line derived from normal melanocytes. We have characterised the expression and phosphorylation status of the main components of the PI3K and MAPK pathways by western blotting and compared this to gene mutation data. Surprisingly we have found that the pattern of pathway utilisation in normal melanocytes was not distinct from those exhibited by the melanoma lines in the presence of serum. However differences become evident in the absence of serum. Thus, we show that early passage metastatic melanoma cell lines have deregulated growth factor signalling pathways in comparison to primary melanocytes, but that this phenomenon is most clearly manifested upon serum withdrawal.
Culture of melanoma cells and melanocytes
The 12 New Zealand melanoma (NZM) cell lines used for this study were generated from metastatic melanoma after written consent was obtained from all patients under Auckland Area Health Board Ethics Committee guidelines as previously described . NZM cell lines were grown under low oxygen conditions (5% O2) in order to mimic physiologically low oxygen levels in tumours. NZM lines were grown in α minimal essential medium (αMEM) (Invitrogen, USA) supplemented with insulin (5 μg/mL), transferrin (5 μg/mL) and sodium selenite (5 ng/mL) (Roche Applied Sciences, Germany), 100 units/mL of penicillin, 100 μg/mL of streptomycin (PS) and 5% fetal bovine serum (FBS). In order to starve cells of serum, culture plates were washed with PBS and incubated with serum free medium (αMEM without FBS and ITS supplement) for 16 hours. Human melanocytes were purchased from Invitrogen and grown in light sensitive Medium 254 supplemented with human melanocyte growth supplement (HMGS-2) (Invitrogen) and PS. Human melanocytes were cultured in an atmosphere of 5% CO2 in air at 37°C.
Genetic analyses of PIK3CA, PTEN, NRAS and BRAF in NZM cell lines
Melanoma cell lines were sequenced for hotspot mutations in BRAF exons 11 and 15 and NRAS exons 1 and 2. The entire coding region of PTEN was also sequenced. The PCR primers for BRAF exon 11 were from a published source  and the full list of PCR primer sequences are shown in Additional file 1. The PCR reactions were conducted using Taq polymerase, supplemented with BSA to prevent melanin poisoning of Taq polymerase .
BRAF, NRAS and PTEN sequencing reactions were conducted using the PCR primers and sequencing primers that were designed to bind to the PCR product, and run using thermal cycle sequencing with Big Dye Terminator 3.1 chemistry (Applied Biosystems, USA). The reactions were run on a 3130XL Applied Biosystems capillary sequencer (DNA Sequencing Facility, University of Auckland). Mutations were detected manually, using the Codon Code aligner 2.0 programme (CodonCode Corporation), and confirmed by repetition of sequencing from separately amplified material.
Screening for mutations was done in all exons of the PIK3CA gene by PCR-single-strand conformational polymorphism (SSCP) as outlined in Campbell et al.  at the Peter MacCallum Cancer Institute in Melbourne, Australia. Mutations were confirmed by sequencing in both directions.
After NZM cells were grown to about 80% confluence in the presence of serum or serum starved for 16 hours, they were washed in ice-cold PBS, lysed in radioimmunoprecipitation assay (RIPA) buffer and prepared for western blotting as previously described . Antibodies used were specific for the following epitopes: phosphorylated PKB at Ser473 and Thr308, phosphorylated p70S6K at Thr389, phosphorylated ribosomal protein S6 at Ser240/244 and 235/236, phosphorylated MEK1/2 at Ser217/221 and phosphorylated ERK1/2 at Thr202/Tyr204. Antibodies recognising total PTEN, PKB, p70S6K, rpS6, MEK1/2 and ERK1/2 were also used. All of the above antibodies were from Cell Signaling Technology (USA). β-actin antibody was from Sigma.
NZM cell line mutations in the PI3K and MAPK pathways
Mutational status of PIK3CA, PTEN, NRAS and BRAF genes in New Zealand Melanoma (NZM) cell lines used for the study
Exon 5 frameshift
Exon 1 frameshift
mutation in exon
Phosphorylation of PKB in melanoma and melanocytes
Phosphorylation of components of the mTOR pathway in melanoma cells and melanocytes
Phosphorylation of components of the ERK pathway in melanoma cells and melanocytes
Previous studies have shown that PIK3CA mutations can lead to hyperactivated PI3K signalling pathways . However, this phenomenon was not consistently observed in all NZM cell lines studied (Figure 3). Our results are similar to that of Morrows et al.,  who observed different patterns of signalling in colon tumour cell lines harbouring the same mutation. They are also consistent with studies by other groups in a range of non-melanoma cell lines [33, 42, 43]. A degree of complexity is provided by the results of a recent study of MCF-7 cells , in which all of the sublines developed from the parental MCF-7 cell line were all expected to have the same PIK3CA mutation, but not all of the sublines showed strong PKB phosphorylation. The results suggest that to some extent the signalling phenotype can be independent of genotype.
All NRAS-only mutant cell lines showed serum-independent phosphorylation of ERK1/2 despite no observable phosphorylation of MEK1/2 (Figure 7). The results are surprising but are consistent with the observation of Pratilas et al. , who found that ERK phosphorylation was not indicative of signalling through the MEK pathway, as ERK phosphorylation is also regulated by negative feedback loops. Furthermore, ERK1/2 is phosphorylated despite little MEK1/2 phosphorylation in some NZM cell lines, suggesting MEK independent regulation of ERK. It has been suggested that PI3K and classical protein kinase C (cPKC) play a major role in the MEK-independent prolonged activation of ERK in some cell types [45, 46]. As all the NZM cell lines used in this study are mutant for either BRAF or NRAS, this suggests that these oncogenic mutations confer activation of the MAPK pathway. However, the dominant signalling pattern observed in all of the NZM cell lines is serum independent phosphorylation of ERK1/2 compared to melanocytes. We also did not observe NZM cell lines lacking PTEN function to be strongly associated with inactivation of MEK1/2 and ERK1/2 in the MAPK pathway as noted by Dan et al. (2010) . A possible explanation for this is that all of the NZM cell lines studied for functional PTEN loss also have BRAF mutations. Although Dan et al.  suggests that mutations in either NRAS or BRAF are strongly correlated with PI3K-PKB pathway inactivation, we did not observe this in the panel of NZM cell lines.
A further result of this study is that, in the presence of serum, the phosphorylation pattern of normal melanocytes is generally similar to that of melanoma cells; differences are more clearly seen when the cell lines are grown in the absence of serum. Unlike melanocytes, melanoma cells are frequently serum independent, may show low phosphorylation in the presence of serum and may show suppression of phosphorylation by the addition of serum. It might be argued that the addition of serum, by stimulating multiple signalling pathways linked to growth factor receptors on the plasma membrane, obscures the signalling pattern derived from an activated component such as PI3K or BRAF, but the data from serum-starved cultures did not provide any clear relationship between mutational status and pathway utilisation. Further experiments with specific inhibitors of these pathways, such as PI3K, PKB, MEK and mTOR prevented phosphorylation of the corresponding downstream target (data not shown), indicating that actions of inhibitors does not depend on activation of upstream signalling molecules. The difference in the dependence of melanocytes and melanoma cells on serum growth factors for phosphorylation of downstream signalling molecules could be due to autocrine growth factors produced in melanomas. It has been noted that melanomas produce vascular endothelial growth factor (VEGF) [48, 49] and fibroblast growth factor (FGF) , which could explain this loss of serum dependence. Melanomas may also over-express growth factor receptors such as insulin-like growth factor 1 receptor (IGF1-R)  and Axl  which can support constitutive activation of some components of the growth factor pathway.
In conclusion, we found that activation of the growth factor signalling pathways varied considerably among a series of NZM cell lines, and that no consistent relationship was observed between pathway activation, as measured by protein phosphorylation. However despite this heterogeneity, there was clearly an observable difference between melanoma cells and normal melanocytes upon serum starvation in growth factor signalling pathways amongst the NZM cell lines. Therefore, the main difference found between normal melanocytes and melanoma cells in culture was the serum dependence of pathway utilisation. Although the sensitivity of the cells harbouring different mutations to inhibitors of the PI3K and MAPK pathways is currently being investigated, unpredictable signalling activation patterns observed in response to mutations suggest that sensitivity to inhibitors between cell lines harbouring the same mutation may be highly variable. Our findings in cultured melanoma cells suggest that the presence of activated PI3K or BRAF does induce consistent, albeit unexpected changes in global cellular signalling. Also, it is possible that different signals arising from mutations in other pathways can crosstalk with the studied pathways to produce unpredictable responses as we have observed. Microenvironmental influences (such as paracrine signalling) may alter the utilisation of a certain signalling pathway over another. Although we measured phosphorylation status as readout for signalling pathway activation, a more comprehensive analysis of downstream signalling pathways such as transcriptional readout  and analysis of the proliferation of cell lines in response to various inhibitors  is expected to give a better understanding of growth factor signalling pathways in melanoma. Moreover, epigenetic regulation may play a greater part in dictating pathway activation independent of activating oncogenes or loss of tumour suppressor mutations, which will produce heterogeneity.
- Gray-Schopfer V, Wellbrock C, Marais R: Melanoma biology and new targeted therapy. Nature. 2007, 445 (7130): 851-857. 10.1038/nature05661.View ArticlePubMed
- Tsatmali M, Ancans J, Thody AJ: Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem. 2002, 50 (2): 125-133. 10.1177/002215540205000201.View ArticlePubMed
- Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G: Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol. 2009, 34 (6): 1481-1489.PubMed
- Inamdar GS, Madhunapantula SV, Robertson GP: Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010, 80 (5): 624-637. 10.1016/j.bcp.2010.04.029.PubMed CentralView ArticlePubMed
- Dhillon AS, Hagan S, Rath O, Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 2007, 26 (22): 3279-3290. 10.1038/sj.onc.1210421.View ArticlePubMed
- Leslie NR, Downes CP: PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004, 382 (Pt 1): 1-11.PubMed CentralView ArticlePubMed
- Wang X, Proud CG: The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 2006, 21: 362-369. 10.1152/physiol.00024.2006.View Article
- Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA. 2008, 105 (45): 17414-17419. 10.1073/pnas.0809136105.PubMed CentralView ArticlePubMed
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 2002, 417 (6892): 949-954. 10.1038/nature00766.View ArticlePubMed
- Omholt K, Platz A, Kanter L, Ringborg U, Hansson J: NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression. Clin Cancer Res. 2003, 9 (17): 6483-6488.PubMed
- Tsao H, Goel V, Wu H, Yang G, Haluska FG: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004, 122 (2): 337-341. 10.1046/j.0022-202X.2004.22243.x.PubMed CentralView ArticlePubMed
- Wong K-K, Engelman JA, Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010, 20 (1): 87-90. 10.1016/j.gde.2009.11.002.PubMed CentralView ArticlePubMed
- Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, Whitcombe D: Multiplexed assays for detection of mutations in PIK3CA. Clin Chem. 2008, 54 (4): 757-760. 10.1373/clinchem.2007.098376.View ArticlePubMed
- Hafner C, Landthaler M, Vogt T: Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol. 2010, 19 (8): e222-e227. 10.1111/j.1600-0625.2009.01056.x.View ArticlePubMed
- Babchia N, Calipel A, Mouriaux F, Faussat A-M, Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Investig Ophthalmol Vis Sci. 2010, 51 (1): 421-429. 10.1167/iovs.09-3974.View Article
- Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009, 41 (5): 544-552. 10.1038/ng.356.PubMed CentralView ArticlePubMed
- Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003, 63 (11): 2881-2890.PubMed
- Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010, 70 (21): 8736-8747. 10.1158/0008-5472.CAN-10-0902.PubMed CentralView ArticlePubMed
- Madhunapantula SV, Robertson GP: The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009, 22 (4): 400-419. 10.1111/j.1755-148X.2009.00585.x.PubMed CentralView ArticlePubMed
- Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD: MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720. Clin Cancer Res. 2011, 17 (4): 721-730. 10.1158/1078-0432.CCR-10-2225.View ArticlePubMed
- Flaherty KT, McArthur G: BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010, 116 (21): 4902-4913. 10.1002/cncr.25261.View ArticlePubMed
- Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010, 363 (9): 809-819. 10.1056/NEJMoa1002011.PubMed CentralView ArticlePubMed
- Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M-K, Attar N, Sazegar H, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010, 468 (7326): 973-977. 10.1038/nature09626.PubMed CentralView ArticlePubMed
- Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010, 468 (7326): 968-972. 10.1038/nature09627.PubMed CentralView ArticlePubMed
- Marshall ES, Finlay GJ, Matthews JH, Shaw JH, Nixon J, Baguley BC: Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst. 1992, 84 (5): 340-345. 10.1093/jnci/84.5.340.View ArticlePubMed
- Charters GA, Stones CJ, Shelling AN, Baguley BC, Finlay GJ: Centrosomal dysregulation in human metastatic melanoma cell lines. Cancer Genetics. 2011, 204 (9): 477-485. 10.1016/j.cancergen.2011.07.001.View ArticlePubMed
- Marshall ES, Matthews JH, Shaw JH, Nixon J, Tumewu P, Finlay GJ, Holdaway KM, Baguley BC: Radiosensitivity of new and established human melanoma cell lines: comparison of [3 H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer. 1994, 30A (9): 1370-1376.View ArticlePubMed
- Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC: Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res. 2000, 12 (3): 149-155.View ArticlePubMed
- Giambernardi TA, Rodeck U, Klebe RJ: Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques. 1998, 25 (4): 564-566.PubMed
- Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64 (21): 7678-7681. 10.1158/0008-5472.CAN-04-2933.View ArticlePubMed
- Kim JE, Shepherd PR, Chaussade C: Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation. Biochem Biophys Res Commun. 2009, 379 (4): 830-834. 10.1016/j.bbrc.2008.12.089.View ArticlePubMed
- Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006, 66 (13): 6546-6552. 10.1158/0008-5472.CAN-06-0384.View ArticlePubMed
- Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, et al: AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009, 16 (1): 21-32. 10.1016/j.ccr.2009.04.012.PubMed CentralView ArticlePubMed
- Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC: Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human Melanoma. J Invest Dermatol. 2008, 128 (8): 2003-2012. 10.1038/jid.2008.30.View ArticlePubMed
- O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, et al: Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res. 2009, 15 (8): 2872-2878. 10.1158/1078-0432.CCR-08-2336.PubMed CentralView ArticlePubMed
- Wang L, Gout I, Proud CG: Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J Biol Chem. 2001, 276 (35): 32670-32677. 10.1074/jbc.M102776200.View ArticlePubMed
- Weinstein IB, Joe A: Oncogene addiction. Cancer Res. 2008, 68 (9): 3077-3080. 10.1158/0008-5472.CAN-07-3293. discussion 3080View ArticlePubMed
- Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, Hazlett JA, Awasthi A, Woolley AG, Marshall ES, Joseph WR, et al: A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One. 2009, 4 (12): e8461-10.1371/journal.pone.0008461.PubMed CentralView ArticlePubMed
- Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ: Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010, 18 (5): 510-523. 10.1016/j.ccr.2010.10.012.PubMed CentralView ArticlePubMed
- Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005, 7 (6): 561-573. 10.1016/j.ccr.2005.05.014.View ArticlePubMed
- Morrow CJ, Gray A, Dive C: Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett. 2005, 579 (23): 5123-5128. 10.1016/j.febslet.2005.07.096.View ArticlePubMed
- Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008, 415 (1): 97-110. 10.1042/BJ20080639.PubMed CentralView ArticlePubMed
- Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC: MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther. 2010, 9 (9): 717-724. 10.4161/cbt.9.9.11432.View ArticlePubMed
- Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N: V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci. 2009, 106 (11): 4519-4524. 10.1073/pnas.0900780106.PubMed CentralView ArticlePubMed
- Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A: PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal. 2010, 22 (9): 1369-1378. 10.1016/j.cellsig.2010.05.006.PubMed CentralView ArticlePubMed
- Grammer TC, Blenis J: Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene. 1997, 14 (14): 1635-1642. 10.1038/sj.onc.1201000.View ArticlePubMed
- Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, et al: Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res. 2010, 70 (12): 4982-4994. 10.1158/0008-5472.CAN-09-4172.View ArticlePubMed
- Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez F, Fabra A: Overproduction of VEGF165 Concomitantly Expressed with its Receptors Promotes Growth and Survival of Melanoma Cells through MAPK and PI3K Signaling. J Investig Dermatol. 2004, 123 (6): 1151-1161. 10.1111/j.0022-202X.2004.23460.x.View ArticlePubMed
- Lacal PM, Ruffini F, Pagani E, D'Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol. 2005, 27 (6): 1625-1632.PubMed
- Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat A-M, Mrzyk S, Mascarelli F: Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Investig Ophthalmol Vis Sci. 2009, 50 (3): 1047-1057.View Article
- Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O: Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors. 2000, 17 (3): 193-202. 10.3109/08977190009001068.View ArticlePubMed
- Shearer RL, Van Ginkel PR, Polans AS: Over-expression of the receptor tyrosine kinase axl promotes ocular melanoma cell survival. Invest Ophthalmol Vis Sci. 2002, 43 (12): 1125-
- Campbell IG, Russell SE, Phillips WA: PIK3CA mutations in ovarian cancer. Clin Cancer Res. 2005, 11 (19): 7042-7043. 10.1158/1078-0432.CCR-05-1024.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/141/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.